<DOC>
	<DOCNO>NCT02707393</DOCNO>
	<brief_summary>In child adolescent chronic myeloid leukaemia ( CML ) stem cell transplantation ( SCT ) may valid alternative life-long treatment tyrosinkinase inhibitor ( TKI ) . This trial aim evaluate use reduce intensity conditioning regimen ( RIC ) , consist fludarabine , melphalan thiotepa order minimize transplant related mortality toxic late effect . Strict post-transplant monitoring reintroduction TKI well donor lymphocyte infusion ( DLI ) case relevant residual disease part protocol .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Children With CML</brief_title>
	<detailed_description>Chronic myeloid leukaemia ( CML ) rare disease child incidence 3-5 % paediatric leukaemia . Since introduction tyrosinkinase inhibitor ( TKI ) stem cell transplantation ( SCT ) long first choice treatment patient early phase CML . However life-long treatment TKI may feasable several case due side effect growth retardation , non-compliance resistance . This protocol evaluate feasibility SCT follow reduce intensity condition regimen ( RIC ) consist fludarabine , melphalan , thiotepa thymoglobuline ( ATG ) . Matched sibling match unrelated donor permit stem cell donation . In case unrelated donor tissue type do high resolution molecular typing . Donors 10/10 9/10 identical allels human leukocyte antigen ( HLA ) system accept . Preferred stem cell source bone marrow peripheral blood stem cell umbilical cord blood also allow . Graft-versus-Host-Disease ( GvHD ) -prophylaxis achieve cyclosporine A mycophenolate mofetil . Monitoring breakpoint cluster region - Abelson ( BCR/ABL ) rearrangement perform monthly first year SCT . In case BCR/ABL positivity TKI give first year SCT . Followed donor lymphocyte infusion ( DLI ) later BCR/ABL positivity persists .</detailed_description>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>child adolescent BCR/ABL positive CML chronic phase , eligible allogeneic stem cell transplantation , irrespective previous treatment strategy availability HLA match sibling donor ( MSD ) , match family donor , match unrelated donor match unrelated cord blood ( MD ) inform consent unavailability MSD MD patient accelerate phase blast crisis pregnancy previous autologous allogeneic SCT inform consent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>stem cell transplantation</keyword>
	<keyword>pediatrics</keyword>
</DOC>